Price$3.26+0.45 (+16.01%)
2026-03-052026-06-08
News · 26 weeks28+250%
2025-12-142026-06-07
Mix2690d
- Insider10(38%)
- Other6(23%)
- SEC Filings6(23%)
- Earnings4(15%)
Latest news
25 items- SECSEC Form 6-K filed by BioLineRx Ltd.6-K - BioLineRx Ltd. (0001498403) (Filer)
- PRBioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update- Announced first patient dosed in Phase 1/2a clinical trial of GLIX1 for treatment of glioblastoma (GBM) -- Announced new GLIX1 data demonstrating potent anti-tumor effect in GBM across multiple in-vivo studies, including a temozolomide (TMZ)-resistant patient-derived xenograft model -- Management to host conference call today, May 27, at 8:30 am EDT -TEL AVIV, Israel, May 27, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its unaudited financial results for the quarter ended March 31, 2026, and provided a corporate update. "Since our last quarterly upda
- SECSEC Form 6-K filed by BioLineRx Ltd.6-K - BioLineRx Ltd. (0001498403) (Filer)
- PRBioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual MeetingTEL AVIV, Israel and OSLO, Norway, May 22, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, and Hemispherian AS, a clinical-stage oncology company developing novel small molecule therapeutics, today announced that two abstracts featuring GLIX1 will be published at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting, which is being held May 29-June 2, 2026, in Chicago, IL. "We are very pleased to have the opportunity to feature these compelling GLIX1 data during this year's ASCO Annual Meeting," stated Philip Serlin, Chief Executive Officer of BioLineRx.
- PRBioLineRx to Report First Quarter 2026 Results on May 27, 2026Management to Hold Conference Call at 8:30 a.m. EDTTEL AVIV, Israel, May 20, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it will release its unaudited financial results for the quarter ended March 31, 2026 on Wednesday, May 27, 2026, before the U.S. markets open. The Company will host a conference call at 8:30 a.m. EDT featuring remarks by Philip Serlin, Chief Executive Officer.To access the conference call, please dial +1-888-407-2553 from the U.S. or +972-3-918-0685 internationally. A live webcast and a replay of the call can be accessed throug
- SECSEC Form 6-K filed by BioLineRx Ltd.6-K - BioLineRx Ltd. (0001498403) (Filer)
- PRBioLineRx and Hemispherian Announce New GLIX1 Data Demonstrating Potent Anti-Tumor Effect in Glioblastoma (GBM) Across Multiple In-Vivo Studies, Including a Temozolomide (TMZ)-Resistant Model with Patient-Derived XenograftsNew preclinical data further demonstrate GLIX1's robust efficacy in a dose-dependent manner, with strong anti-tumor activity observed even at the lowest doses testedResults highlight GLIX1's potential to address the high unmet need for patients with GBMTEL AVIV, Israel and OSLO, Norway, May 19, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a clinical development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, and Hemispherian AS, a clinical-stage oncology company developing novel small molecule therapeutics, today announced highly encouraging new preclinical data that further support the recently initiated Phase 1/2a clinical
- SECSEC Form 6-K filed by BioLineRx Ltd.6-K - BioLineRx Ltd. (0001498403) (Filer)
- PRBioLineRx and Hemispherian Announce First Patient Dosed in Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)Patient was dosed at NYU Langone Health under the supervision of Dr. Alexandra Miller, Chief of Neuro-Oncology & Co-Director of Brain and Spine Tumor Center, Perlmutter Cancer CenterData from the Phase 1 part of the study anticipated in H1 2027TEL AVIV, Israel, and OSLO, Norway, April 28, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a clinical development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, and Hemispherian AS, a clinical-stage oncology company developing novel small molecule therapeutics, today announced that the first patient has been dosed in the first-in-human, Phase 1/2a study of GLIX1 for the treatment of re
- INSIDERSEC Form 3 filed by new insider Yan Shaoyu3 - BioLineRx Ltd. (0001498403) (Issuer)
- INSIDERSEC Form 3 filed by new insider Panem Sandra3 - BioLineRx Ltd. (0001498403) (Issuer)
- INSIDERSEC Form 3 filed by new insider Hofstein Raphael3 - BioLineRx Ltd. (0001498403) (Issuer)
- INSIDERSEC Form 3 filed by new insider Dar Rami3 - BioLineRx Ltd. (0001498403) (Issuer)
- INSIDERSEC Form 3 filed by new insider Molcho Avraham3 - BioLineRx Ltd. (0001498403) (Issuer)
- INSIDERSEC Form 3 filed by new insider Cohen Gal Avraham3 - BioLineRx Ltd. (0001498403) (Issuer)
- INSIDERSEC Form 3 filed by new insider Schwartz Aharon3 - BioLineRx Ltd. (0001498403) (Issuer)
- SECAmendment: SEC Form 20-F/A filed by BioLineRx Ltd.20-F/A - BioLineRx Ltd. (0001498403) (Filer)
- INSIDERSEC Form 3 filed by new insider Serlin Philip A3 - BioLineRx Ltd. (0001498403) (Issuer)
- SECSEC Form 6-K filed by BioLineRx Ltd.6-K - BioLineRx Ltd. (0001498403) (Filer)
- PRBioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)GLIX1, a TET2 activator, is a first-in-class, oral, small molecule targeting DNA damage response in glioblastoma and other cancers GLIX1 has demonstrated potent anti-tumor activity in multiple GBM models, excellent blood-brain barrier penetration and a favorable safety profile in preclinical toxicology studiesStudy is being conducted by world-leading glioblastoma investigators, led by Dr. Roger Stupp TEL AVIV, Israel, March 26, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a clinical development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced the initiation of a first-in-human, Phase 1/2a study of GLIX1 for th
- SECSEC Form 6-K filed by BioLineRx Ltd.6-K - BioLineRx Ltd. (0001498403) (Filer)
- SECSEC Form 20-F filed by BioLineRx Ltd.20-F - BioLineRx Ltd. (0001498403) (Filer)
- PRBioLineRx Reports 2025 Financial Results and Provides Corporate Update- On track to initiate Phase 1/2a clinical trial of GLIX1 for treatment of glioblastoma (GBM) by end of this month -- GLIX1 is positioned to potentially address unmet needs for novel and more effective cancer treatments by targeting DNA damage response mechanisms -- Management to host conference call today, March 23, at 8:30 am EDT -TEL AVIV, Israel, March 23, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its audited financial results for the year ended December 31, 2025, and provided a corporate update. "Since our last quarterly update, we have been
- INSIDERSEC Form 3 filed by BioLineRx Ltd.3 - BioLineRx Ltd. (0001498403) (Issuer)
- INSIDERSEC Form 3 filed by BioLineRx Ltd.3 - BioLineRx Ltd. (0001498403) (Issuer)
BLRX FAQ
5 questionsWhat does BioLineRx Ltd. do?
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of solid tumors, hematological malignancies, and stem cell mobilization; AGI-134, an immuno-oncology agent in the development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the...Where does BLRX stock trade?
BioLineRx Ltd. (BLRX) is listed on NASDAQ.What sector and industry is BLRX in?
BioLineRx Ltd. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What companies are similar to BLRX?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare BLRX side-by-side with any of them on Quantisnow.How can I track BLRX on Quantisnow?
Quantisnow aggregates BioLineRx Ltd.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BLRX to receive live email and push alerts on every new disclosure.